Keywords: Merck Serono, Merck KGaA, NSCLC vaccine, L-BLP25, Stimuvax, Ph III, Oncothyreon

Merck Serono NSCLC vaccine candidate fails to meet primary endpoint in Ph III

Article | 20 December 2012

Print This

Merck Serono, a division of Germany’s Merck KGaA (MRK: DE), Darmstadt, says that the Phase III START trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in